Peregrine Pharmaceuticals (NASDAQ:PPHM)

CAPS Rating: 2 out of 5

A biopharmaceutical company with a portfolio of clinical stage and pre-clinical product candidates using monoclonal antibodies for the treatment of cancer and viral diseases.

Recs

0
Player Avatar pavlos1971 (99.63) Submitted: 1/8/2013 10:08:56 AM : Underperform Start Price: $2.68 PPHM Score: +22.39

Here we go again.

Featured Broker Partners


Advertisement